BCTXW (BriaCell Therapeutics) OCF Margin %: 0.00% (As of Apr. 2026)


BCTXW BriaCell Therapeutics Corp BCTXW
23 GF Score
Price $0.00
! 2 Warning Signs
View Full Analysis

What is BriaCell Therapeutics OCF Margin %?

BriaCell Therapeutics BCTXW 23 OCF Margin % is 0.00% as of Apr. 2026. GuruFocus rates BCTXW with a GF Score™ of 23/100. The stock has 2 warning signs investors should review. Among 959 Biotechnology companies, BriaCell Therapeutics ranks worse than 104275.18% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. BriaCell Therapeutics's Cash Flow from Operations for the three months ended in Apr. 2026 was $-7.02 Mil. BriaCell Therapeutics's Revenue for the three months ended in Apr. 2026 was $0.00 Mil. Therefore, BriaCell Therapeutics's OCF Margin % for the quarter that ended in Apr. 2026 was 0.00%.

As of today, BriaCell Therapeutics's current OCF Yield % is -116.70%.

The historical rank and industry rank for BriaCell Therapeutics's OCF Margin % or its related term are showing as below:


BCTXW's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -66.52
* Ranked among companies with meaningful OCF Margin % only.

BriaCell Therapeutics OCF Margin % Related Terms

BriaCell Therapeutics OCF Margin % Historical Data

* Premium members only.

The historical data trend for BriaCell Therapeutics's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BriaCell Therapeutics OCF Margin % Chart

BriaCell Therapeutics Annual Data
Trend Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23 Jul24 Jul25
OCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

BriaCell Therapeutics Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
BCTXW
23GF Score
BriaCell Therapeutics Corp BCTXW
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BriaCell Therapeutics OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

BriaCell Therapeutics's OCF Margin for the fiscal year that ended in Jul. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Jul. 2025 )/Revenue (A: Jul. 2025 )
=-28.171/0
= %

BriaCell Therapeutics's OCF Margin for the quarter that ended in Apr. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Apr. 2026 )/Revenue (Q: Apr. 2026 )
=-7.02/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
BriaCell Therapeutics (BCTXW) has a OCF Margin % of 0.00% as of Apr. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on BriaCell Therapeutics and its competitors. According to the industry distribution chart, BriaCell Therapeutics ranks #999999 out of 959 companies in the Biotechnology industry.
Is BriaCell Therapeutics' OCF Margin % too high?
BriaCell Therapeutics' current OCF Margin % is 0.00%. Based on the distribution chart, BriaCell Therapeutics ranks #999999 out of 959 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, BriaCell Therapeutics has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does BriaCell Therapeutics' OCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BriaCell Therapeutics ranks #999999 out of 959 companies for OCF Margin %. This places BriaCell Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on BriaCell Therapeutics and its competitors. BriaCell Therapeutics's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BriaCell Therapeutics stock overvalued right now?
BriaCell Therapeutics (BCTXW) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. BriaCell Therapeutics' overall GF Score™ is 23/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For BriaCell Therapeutics (BCTXW), the current OCF Margin % is 0.00% as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BriaCell Therapeutics Business Description

Address 235-15th Street, Suite 300, 3rd Floor, Bellevue Centre, West Vancouver, Vancouver, BC, CAN, V7T 2X1
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.
23GF Score

Get the complete analysis for BCTXW

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price